$137.16
−0.23%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
14.6x
EV/EBITDA
13.6x
Market Cap
$260.70B
MomentumView details →
1D Return
−0.23%
YTD Return
−0.06%
RSI (14)
32.2
ValuationView details →
P/E (Fwd)
14.6x
EV/EBITDA
13.6x
Market Cap
$260.70B
RSI (14)
32.2
MomentumView details →
1D Return
−0.23%
YTD Return
−0.06%
SummaryUpdated Jun 1, 2026
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation founded in 1996 through the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, Novartis has evolved into one of the world's largest pharmaceutical companies, focusing on innovative prescription medicines across multiple therapeutic areas. The company completed a significant strategic transformation in 2023 by spinning off its generics division Sandoz, allowing it to focus entirely on developing and commercializing breakthrough treatments for serious diseases.
Similar companies
Latest newsMore news →
Novartis shares slumped 11% in one day, wiping nearly $30 billion off its market value, after the failure of the muscle-wasting disorder drug del-desiran in a late-stage study.2d agoIn US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.3d agoArtisan Partners, a shareholder of Novartis AG, publicly urged the Swiss drugmaker to shake up its board and overhaul its M&A approach after share declines following three clinical trial setbacks.3d ago